TAGRISSO™ (osimertinib) tablet is a registered trade mark of AstraZeneca Pharmaceuticals LP
Facts of TAGRISSO™
- Medicine Name: TAGRISSO™
- Medicine Name: osimertinib
- Company Name: AstraZeneca Pharmaceuticals LP
What is TAGRISSO™?
TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Tagrisso™
Osimertinib is the generic name for the trade drug Tagrisso™. In some cases, health care professionals may use the trade name Tagrisso™ when referring to the generic drug name osimertinib.
Drug Type: Osimertinib is a targeted therapy. It is an oral EGFR Kinase inhibitor – (For more detail, see “How this drug works,” below.)
What osimertinib is used for:
- For the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by FDA-approved test, who have progressed on or after EGFR TKII therapy.
Note: if a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.